FDA’s OPDP Warns Insomnia Drugmaker Over Email

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Sep 27, 2019 at 9:42 AM.

  1. #1 cafead, Sep 27, 2019 at 9:42 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,028
    Likes Received:
    3
    via The US Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion (OPDP) sent a warning letter to Atlanta-based Galt Pharmaceuticals for an email it sent that makes false or misleading claims related to its insomnia treatment Doral (quazepam), which FDA said are “extremely concerning from a public health perspective.”

    article source
     
    Quote

  2. #2 anonymous, Feb 25, 2020 at 10:22 AM
    anonymous

    anonymous Guest

     
    Quote
  3. #3 anonymous, Feb 25, 2020 at 10:25 AM
    anonymous

    anonymous Guest

    someone from home office advised me not to leave behind a sales aid with data because they know it’s a sketchy claim.
     
    Quote
Reply to Thread